AdAlta (ASX:1AD) has announced results from its Phase 1 extension study of lead asset AD-214 in development for fibrotic diseases, including the debilitating and fatal disease Idiopathic Pulmonary Fibrosis. …
AdAlta announces positive results from Phase 1 extension study of lead asset AD-214
March 6, 2024 Australian Biotech
Latest Video
New Stories
-
Experienced innovation leader joins AusBiotech as its Head of Investment
August 13, 2025 - - Australian Biotech -
Government review and action timelines are in 'dog years' compared to AI
August 13, 2025 - - Latest News -
Australia is not alone in tripping over reform of medical device funding frameworks
August 12, 2025 - - Latest News -
Biogen announces leadership transition for Australia and New Zealand
August 12, 2025 - - Latest News -
If the cost of this process is truly rising at this rate, then the process must be the problem
August 12, 2025 - - Latest News -
Pharmac announces plan to update access and supply of COVID-19 treatments
August 12, 2025 - - Latest News -
Syntara receives FDA guidance for amsulostat in myelofibrosis treatment
August 11, 2025 - - Australian Biotech